本帖最后由 老马 于 2013-3-13 13:43 编辑 7 q+ I- E( }7 |3 z! C7 t; D
3 P- V g% o* [2 N4 t
健择（吉西他滨）+顺铂+阿瓦斯汀
8 q6 ^0 \* s J Gemzar +Cisplatin + Avastin
0 U$ B7 B2 z. Rhttp://annonc.oxfordjournals.org/content/21/9/1804.full- r# ^- E! d; w
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ) w3 V& ]& q8 k# N) G, ~
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
f1 F& w0 r5 J# Z9 z1 M4 @' L# zResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 c6 s2 E1 S K- R! o8 k; k
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 824)
, { {5 M6 J: p华为网盘附件：
7 }4 x) Q5 [) ]# b【华为网盘】ava.JPG
5 e$ D3 f- F0 |" f |
显身卡
